Cardiol Therapeutics (CRDL) joins H.C. Wainwright BioConnect investor Fireside Chat at NASDAQ

Rhea-AI Filing Summary

Cardiol Therapeutics Inc. filed a Form 6-K announcing it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York on May 19, 2026 at 1:30 p.m. EDT. A live webcast and 90-day replay will be available through the Investors section of the company’s website.

The filing also highlights Cardiol as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead drug candidate, CardiolRx™, is being studied in recurrent pericarditis in the Phase II MAvERIC-Pilot study and the ongoing pivotal Phase III MAVERIC trial, and has U.S. FDA Orphan Drug Designation for pericarditis. Cardiol has also completed the Phase II ARCHER study in acute myocarditis and is developing CRD-38, a novel subcutaneous formulation aimed at inflammatory heart disease including heart failure.

Key Terms

Orphan Drug Designation, Phase III MAVERIC trial, recurrent pericarditis, acute myocarditis, +1 more

5 terms

Orphan Drug Designation regulatory

"The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

Phase III MAVERIC trial medical

"the ongoing pivotal Phase III MAVERIC trial (NCT06708299)"

recurrent pericarditis medical

"The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis"

Inflammation of the thin sac around the heart that comes back after a first episode. Like a door that keeps sticking shut even after being fixed, recurrent pericarditis involves repeated bouts of chest pain, fever, or fatigue that can require ongoing treatment, tests, or even procedures. Investors track it because recurrent disease affects healthcare spending, drug trial design, regulatory review, and the potential market for therapies aimed at preventing or managing flare-ups.

acute myocarditis medical

"specifically in acute myocarditis--an important cause of acute and fulminant heart failure"

Acute myocarditis is a sudden inflammation of the heart muscle that can weaken the heart’s ability to pump and cause irregular rhythms, often requiring medical treatment or hospitalization. For investors, it matters because cases can affect employee or executive health, trigger product safety or clinical-trial concerns, increase medical and legal costs, and prompt regulatory scrutiny—similar to how a jammed pump can slow down an entire factory’s output and raise repair bills.

subcutaneously administered medical

"CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease"

A subcutaneously administered treatment is given by injecting medication just under the skin into the fatty layer, like placing a small dose into a shallow pocket beneath the surface rather than into a muscle or a vein. For investors, this matters because such delivery can make therapies easier for patients to self-administer, reduce clinic visits, and affect manufacturing, packaging, and reimbursement, all of which influence market adoption and cost structure.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated May 14, 2026 - Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: May 14, 2026	By:	/s/ Christopher Waddick
		Christopher Waddick
	Title:	Chief Financial Officer

EXHIBIT 99.1

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

TORONTO, May 14, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York, NY, on May 19, 2026, at 1:30 p.m. EDT.

A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/). The replay will be available for 90 days following the conference.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis--an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure--a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission (as part of its Annual Report on Form 40-F) on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-participate-in-fireside-chat-at-hc-wainwright-4th-annual-bioconnect-investor-conference-at-the-nasdaq-302772040.html

SOURCE Cardiol Therapeutics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2026/14/c2256.html

%CIK: 0001702123

For further information: For further information, please contact: Investor.relations@cardiolrx.com

CO: Cardiol Therapeutics Inc.

CNW 07:27e 14-MAY-26

FAQ

What did Cardiol Therapeutics (CRDL) announce in its latest Form 6-K?

Cardiol Therapeutics announced participation in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference, held at the NASDAQ. The event occurs on May 19, 2026, with a webcast and 90-day replay available via the company’s investor website.

When and where will Cardiol Therapeutics’ BioConnect Fireside Chat take place?

The Fireside Chat will take place at the NASDAQ in New York on May 19, 2026, at 1:30 p.m. EDT. Investors can access a live webcast and replay for 90 days in the Events & Presentations section of Cardiol’s investor website.

What is Cardiol Therapeutics’ lead drug candidate CardiolRx™ being developed for?

CardiolRx™ is being developed as an anti-inflammatory and anti-fibrotic therapy for heart disease, including recurrent pericarditis and acute myocarditis. It modulates inflammasome pathway activation, an intracellular process linked to inflammation and fibrosis in these cardiac conditions.

Which clinical programs are evaluating CardiolRx™ for recurrent pericarditis and myocarditis?

For recurrent pericarditis, CardiolRx™ is evaluated in the completed Phase II MAvERIC-Pilot study and the ongoing pivotal Phase III MAVERIC trial. For acute myocarditis, it was studied in the completed Phase II ARCHER trial, which assessed safety, tolerability, and efficacy in affected patients.

Does CardiolRx™ have any special regulatory status with the U.S. FDA?

Yes, the U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis. This designation is intended for therapies targeting rare diseases and can provide incentives related to development and potential commercialization.

What is CRD-38 and what condition is Cardiol Therapeutics targeting with it?

CRD-38 is a novel subcutaneously administered drug formulation being developed for inflammatory heart disease, including heart failure. Heart failure is described as a leading cause of death and hospitalization in developed countries, with large associated healthcare costs in the United States.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-991 NEWS RELEASE DATED MAY 14, 2026 8.3 KB